POP-MED: Population Health Approach to Optimizing Medications in Older Adults
Study Details
Study Description
Brief Summary
This randomized controlled pragmatic pilot study is aimed at examining the feasibility and acceptability of a population health-based deprescribing intervention that leverages the a registry and polypharmacy risk prediction model. It includes four arms (2 intervention and 2 control arms) and uses a parallel arm study design.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This pilot clinical trial is aimed at examining the feasibility and acceptability of a medication management intervention that uses risk stratification to identify older adults (including older adults with Mild Cognitive Impairment or Alzheimer's Disease and Related Dementias) at greatest risk for polypharmacy-related adverse events. The intervention will use a risk prediction model to identify potential study participants for inclusion and will enroll these study participants and their care partners into a polypharmacy clinic. The study will stratify patients by cognitive impairment status. The risk prediction model includes variables such as: age, sex, recent healthcare encounters, current and past medications, current and past lab tests, current and past diagnoses.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Patient-tailored deprescribing assessment and intervention (MCI and Dementia diagnosis) Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors, identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results with the primary care clinician (PCP). Once the PCP has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling and will follow-up with the patient at least once per month to assess side effects, adverse effects, and provide support. This arm specifically includes only patients with a diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment. |
Behavioral: Patient-tailored deprescribing assessment and intervention
Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
|
| No Intervention: Usual care (MCI and Dementia diagnosis) Patients in the comparator arm will see their primary care clinician as needed. This arm specifically includes patients with a diagnoses of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment. |
|
| Experimental: Patient-tailored deprescribing assessment and intervention (no MCI and Dementia diagnosis) Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors, identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results with the primary care clinician (PCP). Once the PCP has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling and will follow-up with the patient at least once per month to assess side effects, adverse effects, and provide support. This arm specifically includes only patients with NO diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment. |
Behavioral: Patient-tailored deprescribing assessment and intervention
Patients are identified for enrollment via a risk prediction model and enrolled in a pharmacist-led polypharmacy clinic. The pharmacist will conduct a comprehensive medication review, which will include: medication reconciliation, assessment of patient risk factors (clinical, socioeconomic), identification of potentially inappropriate medications, identification of potential prescribing omissions, shared decision-making with the patient and/or caregiver, and confirmation of the results of the comprehensive medication review with the primary care clinician. Once the primary care clinician has approved the recommendations, the pharmacist will make the appropriate changes to the medication regimen, will provide tailored medication education and counseling (including Motivational Interviewing) and will follow-up with the patient at least once per month via video visit or phone to assess side effects, adverse effects, and provide support.
|
| No Intervention: Usual care (no MCI and Dementia diagnosis) Patients in the comparator arm will see their primary care clinician as needed. This arm specifically includes patients with NO diagnoses of Mild Cognitive Impairment (MCI) or Alzheimer's Disease and Related Dementias (ADRD) at enrollment. |
Outcome Measures
Primary Outcome Measures
- Composite measure of healthcare utilization [12 months after enrollment]
We will sum up the number of same-hospital all-cause emergency department (ED) and inpatient visits for each study participant in all arms at 12 months.
Secondary Outcome Measures
- Total number of medications [Baseline, 12 months]
Total number of medications on the medication list, including prescription medications, over-the-counter medications, vitamins, and supplements at 12 months.
- Use of any potentially inappropriate medications [Baseline, 12 months]
Use of any potentially inappropriate medications, defined by the 2022 Beers Criteria Tables 2 and 7
- Total number of potentially inappropriate medications [Baseline, 12 months]
Total number of of potentially inappropriate medications at baseline and 12 months using Beers Tables 2 and 7
- Number of medications with a dose reduction >10% over 12 months [12 months]
We will sum up the number of medications where the study participant has achieved at >10% dose reduction compared to baseline for each study participant at baseline and 12 months in both study arms.
- Number of re-prescription of any medications over 12 months [Baseline, 12 months]
We will sum up the number of medications where the study participant has had any re-prescription of medications which were discontinued for 90 days or more by 12 months in all study arms.
- Medication regimen simplification, measured by counting the number of times per day medications are taken, at baseline and 12 months [Baseline, 12 months]
Each study participant will be coded on a continuous scale the number of times a day medications are taken based on the prescription instructions at baseline and 12 months in all study arms.
- Medicare adherence [Baseline, 12 months]
Each study participant will be coded on a continuous scale extracted by comparing EHR prescriptions and pharmacy claims fills at baseline and 12 months in all study arms.
- Change in risk prediction model score [12 months]
Each study participant's information will be run through the risk prediction model at the end of the study to see if there is a meaningful change (10% or more change) in the risk prediction score from baseline to the end of the study period.
- Number of drug-related problems [Baseline, 12 months]
We will compare the total number of drug-related problems (identified retrospectively by a pharmacist) at baseline and 12 months.
- Number of potential pharmacy recommendations [Baseline, 12 months]
We will compare the total number of potential pharmacist recommendations (identified retrospectively by a pharmacist) at baseline and 12 months.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients will be invited to enroll in the study if they are in the top quintile of risk selected by a risk prediction model of polypharmacy-related adverse events. The risk prediction model includes variables such as: age, sex, recent healthcare encounters, current and past medications, current and past lab tests, current and past diagnoses.
-
65 years of age or older
-
Have a primary care clinician within the Cedars-Sinai Health System who uses MyCSLink (electronic health record used by Cedars-Sinai).
-
Part of a Cedars-Sinai Health System population health registry (e.g., enrolled in an Accountable Care Organization, Medicare Advantage plan, or Primary Care First program)
-
Diagnosis of Mild Cognitive Impairment or Dementia at baseline (for one intervention group) on the problem list
Exclusion criteria include:
-
Patients for whom there is an active substance use disorder (defined by a physician) and thus for whom the intervention may not be appropriate
-
Patients with an organ transplant, who are typically followed by a specialty pharmacist
-
Visits with a Cedars-Sinai Medical Center pharmacist for a polypharmacy consult within the last 12 months
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Cedars-Sinai Medical Center
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY00002056